Billiontoone (NASDAQ:BLLN) CTO David Tsao Sells 20,000 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $102.27, for a total transaction of $2,045,400.00. Following the completion of the transaction, the chief technology officer directly owned 1,000 shares in the company, valued at approximately $102,270. This represents a 95.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Stock Performance

Shares of Billiontoone stock opened at $99.38 on Thursday. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The company has a market cap of $4.57 billion and a PE ratio of 180.69. The company has a 50 day moving average of $89.23 and a 200-day moving average of $87.40. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. During the same period last year, the business earned ($0.39) earnings per share. The business’s revenue was up 83.8% compared to the same quarter last year. As a group, equities research analysts forecast that Billiontoone, Inc. will post 0.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Billiontoone

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Rossby Financial LCC acquired a new stake in shares of Billiontoone during the fourth quarter valued at about $25,000. Wells Fargo & Company MN acquired a new position in shares of Billiontoone in the fourth quarter valued at approximately $76,000. Smartleaf Asset Management LLC acquired a new position in shares of Billiontoone in the fourth quarter valued at approximately $80,000. Nano Cap New Millennium Growth Fund L P bought a new position in Billiontoone in the 4th quarter valued at approximately $82,000. Finally, Renaissance Capital LLC bought a new position in Billiontoone in the 4th quarter valued at approximately $201,000.

Analyst Ratings Changes

BLLN has been the subject of several recent analyst reports. Wells Fargo & Company dropped their price objective on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research report on Thursday, March 5th. BTIG Research lowered their target price on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. JPMorgan Chase & Co. raised their price target on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Finally, Guggenheim lifted their price target on shares of Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $125.29.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.